- New CEO to drive the company’s next phase of global growth
MARTINSRIED, Germany / DURHAM, NC, USA, November 02, 2026 / Biotech Newswire / -- Coriolis Pharma, a leading partner for the research and development of biopharmaceutical medicines, today announced the appointment of Dr. Teun van der Heide as Chief Executive Officer (CEO), effective November 2, 2026.
Dr. van der Heide brings extensive leadership and commercial experience in the pharmaceutical and life sciences industries. His career includes senior positions at Lonza, where he headed the business units Bioscience Solutions and Capsule Delivery Solutions (Capsugel), and most recently at ten23 health, where he served as Chief Business Officer (CBO), overseeing the company's business development and commercial activities.
Drawing on his industry expertise, commercial leadership, and deep understanding of the CDMO industry, Dr. van der Heide will focus on strengthening customer relationships, maintaining high service quality, unlocking new growth opportunities, and further expanding Coriolis Pharma's global presence, particularly in the United States.
“We are delighted to welcome Teun to Coriolis Pharma”, said Dr. Michael Wiggenhorn, Co-Founder and Board Member, Coriolis Pharma. “His industry experience, entrepreneurial mindset, and proven commercial leadership, particularly as Chief Business Officer at ten23 health, make him exceptionally well positioned to strengthen our business and drive our next phase of growth in Europe, the United States, and beyond.”
Dr. Wiggenhorn added: “We also sincerely thank Silvia Steyrer-Gruber for her leadership and contributions to Coriolis Pharma over the past four and a half years and wish her all the best for the future.”
Dr. Teun van der Heide, CEO Coriolis Pharma
For high resolution please click the image.
AI Semantic Keywords: Biotechnology; Biopharmaceutical Preparations; Drug Development; Contract Development and Manufacturing Organization (CDMO); Coriolis Pharma; Dr. Teun van der Heide; Chief Executive Officer (CEO); ten23 health; Pharmaceutical Industry; Life Sciences Industry; Biopharmaceutical Medicines; Biopharmaceutical Research and Development; Commercial Leadership; Business Development; Global Expansion; United States; Europe; Dr. Michael Wiggenhorn; Silvia Steyrer-Gruber
About Coriolis Pharma
Coriolis Pharma is a globally operating contract research and development organization (CRDO) specializing in drug product development, analytical services, and manufacturing services for biological therapeutics. Combining scientific excellence with innovative technologies, including AI-powered in silico modeling, Coriolis helps accelerate and de-risk drug development from early development through market approval. Headquartered in Martinsried near Munich, Germany, with a growing U.S. presence anchored by its headquarters and laboratory in North Carolina, Coriolis supports biopharmaceutical companies worldwide.
For more information, visit www.coriolis-pharma.com and follow Coriolis Pharma on LinkedIn.
Contact
Coriolis Pharma
Bettina von Klitzing-Stückle
Director Marketing and Communication
+49 (0) 151 52613897
This email address is being protected from spambots. You need JavaScript enabled to view it.
Source: Biotech Newswire